Verseon Unveils New Blockchain Technology
September 18 2018 - 5:00AM
Business Wire
Blockchain initiative will enable medical
and pharma companies to fund and accelerate life-saving
developments
Verseon today unveils transformative blockchain technology for
tokenized securities, developed by its wholly owned subsidiary,
BlockRules Ltd. Since its founding in 2002, Verseon’s mission
remains to develop disruptive technologies and products that
advance global health. As part of this goal, the Company is
challenging traditional drug development funding models through the
process of tokenization of securities.
BlockRules technology supports the sale, launch, and trading of
securities on a public blockchain complete with multijurisdictional
regulatory compliance integrated and enforced directly on the
blockchain. This breakthrough permits fully regulated, secure, and
transparent support of securities, including decentralized
trading.
Current blockchain technology has the potential to transform the
global investment landscape. To accomplish that, token offerings
need to comply with existing security regulations if they are to
become ubiquitous. The technology developed by BlockRules is
designed to overcome these regulatory hurdles.
“We founded Verseon with the goal of developing new technologies
to advance the discovery and development of new medicines,” said
Adityo Prakash, CEO of Verseon. “By democratizing investment access
with blockchain technology, we will change the way new medicines
and other life-science innovations are funded and how the resulting
proceeds are shared.”
BlockRules Ltd. plans to offer its technology to innovative
companies ready to embrace the rapidly developing blockchain
community. By bringing regulatory certainty to the blockchain,
BlockRules aims to provide the global investment community with
safer and more relevant opportunities for investment.
“Recent advances in the blockchain space have the potential to
narrow the gap between innovative companies and investors,” said
Neil Woodford, founding partner of Woodford Investment Management.
“Verseon’s innovations in this space address some of the
traditional choke points in capital flow and should lead to a more
efficient market.”
About BlockRules Ltd. BlockRules Ltd., a wholly owned
subsidiary of Verseon, is a blockchain technology company
supporting the sale, launch and trading of securities. By enforcing
multijurisdictional regulatory compliance directly on the
blockchain, the Company facilitates issuance and decentralized
trading that is secure, transparent and verifiable. BlockRules Ltd.
handles the registration of investor KYC (“know your customer”)
information for its products and is providing this service to
prospective investors at https://www.blockrules.com.
About Verseon Verseon Corporation (www.verseon.com, AIM:
VSN) is developing disruptive life-science technology to advance
global health. The clinical-phase Company is using its proprietary,
computational drug discovery platform paired with a comprehensive
in-house chemistry and biology workflow to build a growing drug
development pipeline. Through its wholly owned subsidiary
BlockRules Ltd., Verseon is also pioneering blockchain technology
for regulated securities.
-Ends-
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180918005441/en/
Vane Percy & RobertsFor trade and pharma media
enquiries, please contactSimon Vane Percy+44 (0) 1737 821 890
Verseon (LSE:VSN)
Historical Stock Chart
From Apr 2024 to May 2024
Verseon (LSE:VSN)
Historical Stock Chart
From May 2023 to May 2024